Last updated: February 27, 2026
What is the Drug Associated with NDC 68308-0663?
NDC 68308-0663 corresponds to Mavenclad (cladribine). It is used for multiple sclerosis (MS) treatment, specifically relapsing forms of MS in adults. Mavenclad received FDA approval in August 2019 and is marketed by EMD Serono.
Market Overview
Therapeutic Class and Indications
- Drug Class: Antineoplastic and immunomodulating agents (nucleoside analogs)
- Primary Use: Multiple sclerosis (relapsing-remitting MS and secondary progressive MS)
Market Size and Growth
- Global MS Market: Valued at approximately $21.4 billion in 2022 (GlobalData, 2022).
- Market CAGR (2022-2027): Estimated at 4-6%, driven by increasing diagnosis rates and off-label use.
- U.S. MS Market: Accounted for roughly 45% of the global sales in 2022. The U.S. MS treatment market totaled approximately $9.5 billion.
Competitive Landscape
Utilization Trends
- Increase in MS diagnoses, especially among younger adults.
- Growing acceptance of oral therapies.
- Patient preference for less frequent dosing schedules.
Pricing Dynamics
Current Pricing
- List Price (U.S.): Approximately $79,500 for a 20 mg dose pack, with a treatment course costing about $85,000–$90,000.
- Cost per Year: Estimated at $80,000–$100,000, depending on treatment duration and dosing.
Reimbursement and Payer Dynamics
- High costs result in coverage challenges; many insurers require prior authorization.
- Several patient assistance programs (e.g., EMD Serono Foundations) offer copay support.
- Formulary inclusion depends on competitive positioning, cost-effectiveness, and clinical differentiation.
Market Entry Barriers and Drivers
Barriers
- High pricing limits uptake among cost-sensitive payers.
- Physician familiarity and comfort influence prescription rates.
- Patent exclusivity extends until ca. 2030, limiting generic competition.
Drivers
- Rising MS prevalence.
- Novel oral therapy convenience.
- Positive clinical outcomes and safety profile.
Price Projections (2023–2028)
| Year |
Estimated Average Price ($) |
Notes |
| 2023 |
80,000 |
Stable, pending patent exclusivity and market dynamics |
| 2024 |
78,000–82,000 |
Slight price decrease due to increased competition or biosimilar entry forecasted after patent expiry (~2030) |
| 2025 |
75,000–80,000 |
Potential price compression, contingent on formulary negotiations |
| 2026 |
73,000–78,000 |
Cost-effectiveness evaluations influence price adjustments |
| 2027 |
70,000–75,000 |
Shift toward more competitive biosimilars, if any, may lower prices further |
| 2028 |
68,000–73,000 |
Slight decline expected as generic alternatives emerge post-patent |
Key Factors Affecting Future Pricing
- Patent Expiration: No biosimilar or generic candidates expected before 2030.
- Market Competition: Introduction of emerging therapies or biosimilars could pressure downward pricing.
- Regulatory Changes: Policy and payer reforms affecting drug reimbursement and negotiation leverage.
- Clinical Evidence: New efficacy or safety data can influence market share and pricing strategies.
Conclusion
Mavenclad maintains premium pricing driven by its clinical profile and dosing convenience. Price stability is expected until patent expiry, after which biosimilar competition could reduce costs by 20–30%. Market growth remains strong, supported by increasing MS prevalence and patient preference for oral therapies.
Key Takeaways
- The U.S. market for Mavenclad is approximately $80,000 annually, with slight declines projected ahead.
- Market growth continues, driven by rising MS diagnosis and oral therapy preference.
- Price reductions are anticipated post-patent expiry (~2030) due to biosimilar entries.
- Competitive and reimbursement dynamics will significantly influence future pricing.
- Clinical outcomes and patient adherence influence market share distribution among MS therapies.
FAQs
1. When is Mavenclad's patent expected to expire?
Patent protections extend until approximately 2030, delaying biosimilar or generic competition.
2. How does Mavenclad compare in price to competitors?
It is priced higher than many oral MS drugs like Tecfidera (~$84,000/year) but similar to other high-cost MS therapies like Gilenya (~$85,000/year).
3. What factors could influence a decrease in Mavenclad prices before patent expiry?
Market entry of biosimilars, increased competition, payer negotiations, and policy reforms targeting drug affordability.
4. How does clinical efficacy impact market share?
Clinical efficacy and safety data can enhance market penetration by influencing prescriber confidence and payer reimbursement.
5. Are there ongoing efforts to reduce Mavenclad’s price?
No immediate plans for price reduction are publicly available; cost adjustments are expected after patent expiration with biosimilar competition.
References
- GlobalData. (2022). Global MS Market Analysis Report.
- EMD Serono. (2019). Mavenclad (cladribine) prescribing information.
- IQVIA. (2022). Pharmaceutical Market Outlook.
- BioCentury. (2022). MS Therapies Competitive Landscape.
- FDA. (2019). Mavenclad (cladribine) Approval Announcement.
